logo
An Agile Leadership Lesson In Letting Go

An Agile Leadership Lesson In Letting Go

Forbes7 days ago
Albert Golukhov is the CEO of ExcessLogic, a company specializing in helping businesses optimize their inventory/asset management.
Technological advancement is driving change at an exponential rate. Product cycles are shorter, competitors are more aggressive and market expectations seem to evolve overnight.
For executives, keeping pace is no longer enough. I find that sustained success now demands a new kind of leadership—one grounded in agility, strategic foresight and the courage to make bold decisions under pressure. Sometimes, this even means strategic asset liquidation.
Embracing Agile Leadership
Gone are the days when five-year strategic plans could reliably guide a company's direction. In the current climate, long-term road maps often expire before they're executed. Leaders must embrace agility across all functions. That means shorter planning cycles, fast iteration and real-time responsiveness based on emerging market signals.
Agility, however, starts with people. Building a culture of continuous learning is essential. Teams should be encouraged to experiment, challenge assumptions and adapt to new technologies without fear of failure. The companies that invest in their employees' curiosity and growth—through things like ongoing training, skill development and cross-functional collaboration—can reap the benefits of a workforce that evolves with the business, not behind it.
Equally important is reaching beyond the company's own walls. In high tech, no single organization can master every domain. Forming strategic partnerships with startups, research institutions or even competitors can allow you to accelerate development cycles, share risk and expand capabilities. I encourage you to shift your thinking to ecosystems, not silos, in order to find opportunities where others see threats.
To guide these decisions, data must be at the center. While experience and instinct remain valuable, intuition alone won't cut it in a volatile market. Real-time data analytics—applied across customer insights, operational performance and competitive intelligence—can sharpen strategic direction and reduce costly missteps. The faster you can interpret and act on data, the more resilient your strategy becomes.
Behind all of this must lie a strong financial foundation. High growth gets the headlines, but liquidity is what gets companies through market turbulence. Therefore, you should be a vigilant steward of cash flow, burn rate and cost structures. In periods of volatility or declining revenue, it may be necessary to make tough calls that protect the company's ability to operate and invest in its future.
Strategic Asset Liquidation
One highly effective, yet often underutilized, strategy is the liquidation of noncore or underutilized assets. As the CEO of a company specializing in helping businesses optimize asset management, I've seen how this approach can serve as a powerful lever to support ongoing operations, preserve cash and stabilize the business during times of uncertainty.
Strategic asset liquidation is not about desperation; it's about discipline. It begins with a clear-eyed audit of everything a company owns. This includes physical assets like IT hardware, networking equipment and office infrastructure, but also intangible assets like intellectual property, unused software licenses, real estate and even entire business units that no longer align with the company's strategic goals.
After identifying these assets, the next move is to determine their true market worth and the level of buyer interest. For physical and IT-related equipment, third-party remarketing specialists can help. These firms not only have established networks of buyers but also can handle data security, logistics, compliance and value maximization—greatly reducing legal and operational risks for the seller. Selling assets internally or ad hoc can open a company to unforeseen liability, especially if data isn't properly wiped or environmental disposal isn't compliant with regulatory standards.
For IP or software licenses, expert valuation may also be required. This process may involve consulting legal and industry professionals who can assess current market appetite and guide negotiations with potential buyers or licensees. For larger divestitures—such as an underperforming product line or subsidiary—working with investment bankers or M&A advisors may be the most effective route.
An often-overlooked advantage of asset liquidation is its impact on the company's tax burden. Many jurisdictions assess taxes based on a company's assets. By shedding excess or nonfunctional assets, businesses can reduce their long-term tax liabilities while also improving their balance sheet and operational efficiency.
Crucially, asset liquidation provides immediate capital that can be reinvested with intent. Proceeds should be directed toward high-priority initiatives: critical R&D efforts, essential staffing or near-term growth strategies. This is not just about staying afloat; it's about reallocating trapped resources to areas that drive long-term value creation.
Maintaining Stakeholder Trust
Transparency throughout this process is key. Leadership must clearly communicate to investors, employees and other stakeholders why certain assets are being sold, how the proceeds will be used and what the overall strategy entails. When executed with integrity and foresight, asset liquidation becomes not a sign of weakness but a marker of strategic maturity.
The high-tech sector rewards speed, but it punishes waste. Every piece of unused infrastructure, idle license or outdated subsidiary carries a cost—financially and operationally. Asset liquidation, when approached strategically and executed through the right third-party partners, not only generates immediate capital but also strengthens the company's overall health and readiness for what's next.
Agility In Action
In a world defined by volatility, the companies that thrive will not be those that hold on the tightest—but those that know when to let go and reinvest wisely. I believe this is the essence of agile leadership: adapting boldly, allocating resources intelligently and moving at the speed of change.
Forbes Business Council is the foremost growth and networking organization for business owners and leaders. Do I qualify?
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Why UnitedHealth Stock Is Sinking Today
Why UnitedHealth Stock Is Sinking Today

Yahoo

time2 hours ago

  • Yahoo

Why UnitedHealth Stock Is Sinking Today

Key Points UnitedHealth Group's stock declined following its Q2 earnings report, which revealed a significant miss on earnings per share and a lower-than-expected full-year outlook. The company attributed its disappointing guidance to rising medical costs and changes in its business plans. Beyond financial performance, UnitedHealth is facing multiple challenges, including a CEO resignation, two DOJ investigations into Medicare billing, and allegations of unethical practices related to nursing home payments. 10 stocks we like better than UnitedHealth Group › Shares of UnitedHealth Group (NYSE: UNH) are falling on Tuesday, down 5.4% as of 2:20 p.m. ET. The drop comes as the S&P 500 (SNPINDEX: ^GSPC) declined 0.3% and the Nasdaq Composite (NASDAQINDEX: ^IXIC) fell 0.2%. The troubled health insurance giant set worse-than-expected guidance on Tuesday. UnitedHealth continues to struggle The company reported its Q2 financials today, revealing the insurer is still very much struggling. The company was able to deliver on revenue, reporting $111.62 billion versus the expected $111.52 billion, but it missed significantly on earnings per share (EPS), reporting $4.08 per share when Wall Street expected $4.48 per share. More concerning was the company's outlook for the full year. UnitedHealth expects EPS of at least $16 and sales of $445.5 billion to $448 billion. Wall Street's expectations were EPS of at $20.9 and sales of $449.2. The company cited rising medical costs and abandoned "previously planned portfolio actions" as reasons for the disappointing outlook. UnitedHealth's problems mount This latest disappointing quarter is the latest in a series of bad news related to the massive insurer: The company's CEO abruptly stepped down, citing "personal reasons"; it was revealed that the DOJ currently has two investigations into the company's Medicare billing practices; and an exposé published by the Guardian alleges the company was paying nursing homes to keep residents out of the hospital when they needed elevated levels of care. ​​ There are just too many issues facing UnitedHealth at the moment, with no clear picture of an imminent turnaround. I would stay away from the stock. Should you buy stock in UnitedHealth Group right now? Before you buy stock in UnitedHealth Group, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and UnitedHealth Group wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $633,452!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,083,392!* Now, it's worth noting Stock Advisor's total average return is 1,046% — a market-crushing outperformance compared to 183% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025 Johnny Rice has no position in any of the stocks mentioned. The Motley Fool recommends UnitedHealth Group. The Motley Fool has a disclosure policy. Why UnitedHealth Stock Is Sinking Today was originally published by The Motley Fool

Middle management is dead.
Middle management is dead.

Fast Company

time4 hours ago

  • Fast Company

Middle management is dead.

Everyone's obsessing over whether AI will steal their jobs. They're asking the wrong question. While headlines scream about AI replacing workers— 41% of employers are planning to downsize, half of entry-level jobs are vanishing—they're missing the real transformation. The question isn't who gets replaced. It's what happens to everyone who remains. Here's the contrarian truth: AI isn't just eliminating jobs. It's eliminating the entire concept of traditional management. And that may be the best thing that could happen to your career. The great flattening Middle management exists primarily for one reason: to be human routers of information. Managers aggregate data from below, filter it, and pass it upward. They take strategy from above, translate it, and cascade it downward. They're essentially organizational middleware. But what happens when AI can route information instantly, surface insights automatically, and coordinate work seamlessly? The middleware becomes redundant. At Fireflies, we've proven this isn't just a theory. We operate with minimal hierarchy—individual contributors earn more than managers. Our AI captures every conversation, tracks every decision, and ensures nothing falls through the cracks. The result? A radically flat organization where everyone operates like the CEO of their domain. Welcome to the mini-CEO era When information flows freely and AI handles coordination, something profound happens: Every employee gains the context and tools previously reserved for executives. Picture this: A customer success manager (CSM) notices during three client calls that users are struggling with the same feature. Instead of scheduling meetings and writing reports, the CSM queries their AI teammate for pattern analysis across all customer conversations. Within minutes, data shows that 47% of enterprise clients mention this friction point. The AI teammate goes on to draft a feature improvement proposal, tag the product team, and by day's end, it's prioritized for the next sprint. That action used to require three departments and five approval layers. Now it's one person with AI amplification making executive-level decisions. Or consider the sales rep who uses conversational intelligence to track competitor mentions across every sales call in the company. They spot a pricing pattern, adjust their proposal strategy, and close three deals that would have been lost. No sales ops team needed. No pricing committee. Just real-time intelligence and autonomous action. This isn't empowerment theater. It's a fundamental reorganization of power. Resistance is futile Traditional organizations will fight this. They'll create 'AI committees' and 'transformation task forces' stuffed with the very middle managers whose roles are evaporating. They'll add layers to manage the technology that's supposed to remove layers. They'll lose. Because while they're debating governance frameworks, their competitors are unleashing armies of mini-CEOs because each employee is armed with AI teammates that multiply their impact tenfold. Each person is making decisions at the speed of thought, not the speed of bureaucracy. It's your move The choice is stark: Evolve or become irrelevant. If you're an employee, start acting like a mini-CEO today. Use AI to expand your scope. Make decisions beyond your pay grade. The old rules are dead. If you're a leader, stop protecting hierarchies that technology has already made obsolete. Give your people AI teammates and radical autonomy. Yes, it's scary to surrender control. But the alternative—watching competitors move at 10 times your speed—is scarier. The future of work isn't about humans versus AI. It's about humans with AI superpowers, operating in radically flat organizations where everyone thinks and acts like an owner.

Aspire Biopharma Holdings, Inc. Announces CEO Transition
Aspire Biopharma Holdings, Inc. Announces CEO Transition

Yahoo

time4 hours ago

  • Yahoo

Aspire Biopharma Holdings, Inc. Announces CEO Transition

Kraig Higginson, Current Chairman of the Board, Appointed Interim CEO ESTERO, FL / / July 30, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), developer of a multi-faceted patent-pending supplement delivery technology, today announced that the Company's Board of Directors (Board) has appointed Kraig Higginson as interim Chief Executive Officer (CEO), effective July 24, 2025. Mr. Higginson serves as Chairman of the Board and previously served as CEO of Aspire for four years. Michael C. Howe has resigned as CEO and as a member of the Board. The Board thanks Mr. Howe for his contributions to the Company and plans to initiate a search for a permanent CEO. "On behalf of the entire Board, I want to thank Michael for his contributions to the Company and wish him the very best in the future," said Kraig Higginson, Interim Chief Executive Officer of Aspire. "I look forward to leading Aspire with the same level of commitment as if I were in the role permanently, with a goal of continuing to execute on maximizing the potential of Aspire's powerful and differentiated drug delivery platform. We are fortunate to have a capable leadership team, and we will continue to focus on positioning the business for long-term success." The Company also announced the resignations of Mr. Gary E. Stein and Ms. Barbara Sher from the Board, effective immediately. The Aspire Board is very grateful for Mr. Steins's and Ms. Sher's outstanding service as members of the Board and for all of the thoughtful insights and valuable contributions they provided during their tenures. In connection with this transition, the Board of Directors appointed Howard Doss, to serve as Director and Chairman of the Audit Committee of the Company, effective immediately. Mr. Doss, age 71, has served as the Chief Financial Officer of PowerUp from August 2023 until February 2025. He is a seasoned chief financial officer and accountant. He served as Chief Financial Officer of Kernel Group Holdings, Inc. In 2021, he served as Chief Financial Officer of Aesther Healthcare Acquisition Corp., a special purpose acquisition company until it consummated its initial business combination in February 2023. He has also served as chief financial officer of Trade Health, Inc., an online marketplace for health traded on Nasdaq under the symbol "SCNX." Mr. Doss has served in a variety of capacities with accounting and investment firms. He joined the staff of Seidman & Seidman (BDO Seidman, Dallas) in 1977 and in 1980 he joined the investment firm Van Kampen Investments, opening the firm's southeast office in Tampa, Florida in 1982. He remained with the firm until 1996 when he joined Franklin Templeton. After working for the Principal Financial Group office in Tampa, Florida, Mr. Doss was City Executive for U.S. Trust in Sarasota, Florida, responsible for high-net-worth individuals. He retired from that position in 2009. He served as CFO and Director for Sansur Renewable Energy, an alternative energy development company, from 2010 to 2012. Mr. Doss has also served as President of Staradio Corp. since 2005. Mr. Doss is a member of the America Institute of CPA's. He is a graduate of Illinois Wesleyan University. About Aspire Biopharma, Inc. Headquartered in Estero, Fl., Aspire Biopharma has developed a disruptive technology that can deliver supplements and drugs rapidly and precisely. For more information, please visit Safe Harbor Statement Certain statements made in this communication are "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may generally be identified by the use of words such as "estimate," "projects," "expects," "anticipates," "forecasts," "plans," "intends," "believes," "seeks," "may," "will," "would," "should," "future," "propose," "potential," "target," "goal," "objective," "outlook" and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding the financial position, business strategy and the plans and objectives of management for future operations. These statements are based on various assumptions, whether or not identified in this communication, and on the current expectations of Aspire's management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on by any investor as a guarantee, an assurance, a prediction or a definitive statement of fact or probability. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside the control of the parties, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law. Aspire Biopharma Holdings, Inc. Contact PCG AdvisoryKevin McGrath+1-646-418-7002kevin@ SOURCE: Aspire Biopharma Holdings, Inc. View the original press release on ACCESS Newswire

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store